Join the HOPE Study

Help advance a new way of treating Alzheimer’s disease

Be part of the development of a new non-invasive wearable study device that delivers sensory stimulation and has the potential to slow the progression of mild to moderate Alzheimer’s disease, from the comfort of home.

Answer a few questions to get started

“The HOPE Study offers a rare opportunity for patients with mild to moderate Alzheimer’s disease to participate in a research study utilizing technology as an intervention.

Our patients and families have expressed great interest in enrolling in this study because it is non-invasive and represents a novel and safe approach to potentially slowing the progression of Alzheimer’s disease.”

– Dr. Michelle Papka, Ph.D., Director and Founder of The Cognitive and Research Center of New Jersey

Why consider a device for the treatment of Alzheimer’s disease?

While many investigational drug treatments directly target widely known amyloid plaques and tau tangles in the brain, Cognito Therapeutics is investigating a unique, non-invasive medical device that targets other contributing factors to Alzheimer’s disease, such as the abnormal electrical activities in the brain.

This approach represents an opportunity to treat Alzheimer’s disease with a new modality and could bring much-needed treatment option to many impacted by this devastating disease.

Dr. Ralph Kern, Chief Medical Officer, Cognito Therapeutics talks about the Hope Study trial

The FDA has granted Breakthrough Device Designation to Cognito’s investigational device for the treatment of cognitive and functional symptoms associated with mild-to-moderate Alzheimer’s disease.

The investigational medical device consists of headphones and eyewear and delivers treatment through sensory stimulation in the comfort of patients’ homes.

Encouraging results from previous studies

The innovative medical device technology currently being evaluated in the HOPE Study emerged from a collaboration between two MIT neuroscientists and has been tested in multiple clinical studies to date.

In a 6-month long phase-2 study, treatment delivered through this investigational device has shown to significantly slow the progression of Alzheimer’s disease through preservation of cognitive and daily function, as well as whole brain volume among treated participants.

Patients across multiple clinical studies have completed over 40,000 treatment sessions to date and tolerated the study device well. No treatment limiting serious adverse events were reported.

“Overall, it was an easy trial, and it was easy to travel with the device”

– Phase 2 Trial Participant

Who can participate in the HOPE Study?

You or a loved one may be eligible to join the study if you/they are:

Between 50 and 90 years of age

Have been diagnosed with Alzheimer’s disease by a healthcare professional

Have a reliable study partner, such as a family member or friend, 
who can help with participation in the study

Meet other criteria which will be evaluated


  • Must not have profound hearing loss
  • Must not have taken Memantine (Namenda or Namzaric) within the past 30 days
  • Must not live in a continuous care nursing facility

What does participation involve?

Participants who choose to enroll in the HOPE Study will:

  • Use a non-invasive wearable study device at home on a daily basis for approximately 12 months. The device incorporates eyeglasses and headphones and delivers sensory stimulation
  • Participate in study-related visits at clinical sites with experienced healthcare professionals
  • Receive compensation for study-related expenses (such as travel) and time, for both the participant and study partner

No drugs or highly invasive procedures

No insurance or out-of-pocket payments necessary

Ready to help advance treatment for Alzheimer’s disease?

Ready to help advance treatment for Alzheimer’s disease?

Start Here